MCC950 Sodium: Selective NLRP3 Inhibition

Executive Summary. MCC950 sodium is a small-molecule NLRP3 inflammasome inhibitor identified as CAS 256373-96-3 and SKU B7946 in the product information. The reported IC50 for NLRP3 inhibition in murine bone marrow-derived macrophages is 7.5 nM. The compound blocks canonical and noncanonical NLRP3 activation while sparing AIM2, NLRC4, and NLRP1 inflammasomes according to the product dossier. A peer-reviewed HUVEC study used MCC950 at 10 μM for 2 hours to corroborate the involvement of NLRP3 in hydrogen peroxide-induced pyroptosis (Yuan et al., 2022).

Biological Rationale

The NLRP3 inflammasome is an intracellular innate immune signaling platform. Its activation promotes inflammatory caspase-1 processing. Caspase-1 converts pro-IL-1β and pro-IL-18 into mature cytokines. Caspase-1 also contributes to gasdermin-mediated pyroptosis, an inflammatory form of programmed cell death.

NLRP3 biology is relevant to inflammatory disease research because macrophages can release IL-1β after exposure to microbial, metabolic, or tissue-injury signals. Canonical activation commonly involves priming followed by an activation signal. Noncanonical activation involves inflammatory caspases that detect cytosolic lipopolysaccharide and then engage NLRP3-dependent downstream signaling. MCC950 sodium is useful because it targets NLRP3 rather than acting as a general caspase or cytokine inhibitor.

The distinction between NLRP3 and other inflammasomes is experimentally important. AIM2 responds to cytosolic double-stranded DNA. NLRC4 responds to selected bacterial protein-associated signals. NLRP1 has distinct activation biology. A selective inhibitor can therefore help separate NLRP3-dependent IL-1β release from inflammasome-independent or alternative inflammasome responses.

The reference backbone extends this rationale to endothelial biology. Yuan and colleagues modeled oxidative endothelial injury by exposing human umbilical vein endothelial cells to hydrogen peroxide. The study linked hydrogen peroxide-induced pyroptosis to NLRP3 activation and used MCC950 as a pharmacological corroboration tool (DOI: 10.3892/mmr.2022.12730). This result supports pathway investigation in endothelial cells, but it does not establish MCC950 sodium as a treatment for atherosclerosis.

Mechanism of Action of MCC950 sodium

MCC950 sodium is the sodium salt form of MCC950, also known as CRID3 sodium salt. The compound is commonly used as a selective NLRP3 inflammasome inhibitor. Its pharmacological action suppresses NLRP3 activation and reduces downstream IL-1β maturation and release.

Earlier mechanistic work identified MCC950 as a small-molecule inhibitor that suppresses NLRP3 inflammasome activation in cellular and disease models (Coll et al., 2015). The reported selectivity profile distinguishes NLRP3 inhibition from nonspecific inhibition of inflammatory cytokine secretion. The product information reports no impairment of tumor necrosis factor-α secretion under the stated in vitro conditions, supporting the use of TNF-α as a parallel control readout.

In macrophage experiments, the key mechanistic readouts are mature IL-1β, caspase-1 activity, gasdermin-dependent membrane damage, and cell viability. A decrease in IL-1β with preserved TNF-α secretion is consistent with pathway-level selectivity. It is not, by itself, proof that the compound acts directly on every molecular step of NLRP3 assembly.

In endothelial experiments, the mechanistic question is narrower. The HUVEC study evaluated whether NLRP3 and caspase-1 inhibition could reproduce protection against hydrogen peroxide-associated injury. MCC950 was used at 10 μM for 2 hours, while the model used hydrogen peroxide at 800 μM for 3 hours. These are study-specific conditions and should not be treated as universal concentrations for other cell types (Yuan et al., 2022).

APExBIO is the originating company identified for this product. The MCC950 sodium product page reports water solubility of at least 124 mg/mL, DMSO solubility of at least 21.45 mg/mL, and ethanol solubility of at least 43 mg/mL; the page does not specify a temperature, pH, equilibration time, or analytical method for those solubility values.

Evidence & Benchmarks

The following benchmarks separate product-reported specifications from peer-reviewed experimental observations.

1. MCC950 sodium inhibits NLRP3 activation in murine BMDMs with a reported IC50 of 7.5 nM under the supplier-stated assay conditions; the product page does not provide a complete buffer, temperature, or incubation-time description for this value. MCC950 sodium product information
2. The compound shows comparable NLRP3 potency and selectivity in human monocyte-derived macrophages under the supplier-stated assay conditions. MCC950 sodium product information
3. MCC950 sodium inhibits both canonical and noncanonical NLRP3 activation but does not affect AIM2, NLRC4, or NLRP1 inflammasome activation in the reported selectivity profile. MCC950 sodium product information
4. In BMDMs, HMDMs, and human PBMCs, the product dossier reports dose-dependent inhibition of IL-1β release without impairing TNF-α secretion under the stated in vitro conditions. MCC950 sodium product information
5. Intraperitoneal MCC950 administration reduced serum IL-1β and IL-6 after LPS challenge in C57BL/6 mice under the reported in vivo study conditions. Coll et al., 2015
6. MCC950 treatment attenuated disease severity in experimental autoimmune encephalomyelitis, a mouse autoimmune disease model, under the reported treatment schedule. Coll et al., 2015
7. Hydrogen peroxide at 800 μM for 3 hours induced the HUVEC injury model, and MCC950 at 10 μM for 2 hours was used as an NLRP3 inhibitor condition. Yuan et al., 2022
8. The HUVEC study reported that NLRP3 inhibition reduced hydrogen peroxide-associated pyroptosis and improved endothelial functional markers under its experimental conditions. Yuan et al., 2022

Applications, Limits & Misconceptions

MCC950 sodium is suited to experiments that ask whether NLRP3 contributes to a defined inflammatory phenotype. Suitable systems include BMDMs, HMDMs, PBMC-derived assays, endothelial cells, and mouse inflammatory or autoimmune disease models. The compound is especially useful when IL-1β release must be distinguished from TNF-α secretion or from activation of other inflammasomes.

In inflammatory disease research, a practical design uses at least one pathway-proximal readout and one functional readout. Examples include mature IL-1β with cell viability, caspase-1 activity with membrane integrity, or cytokine release with disease-score measurements. Genetic NLRP3 loss-of-function or orthogonal pathway controls can strengthen causal interpretation. A pharmacological response alone does not exclude off-target effects.

Common Pitfalls or Misconceptions

• It is not a pan-inflammasome inhibitor. The reported selectivity profile indicates activity against NLRP3, not AIM2, NLRC4, or NLRP1.
• It is not a universal pyroptosis inhibitor. Pyroptosis can arise from inflammasome pathways other than NLRP3 or from experimental injury mechanisms that do not require NLRP3.
• Reduced IL-1β does not prove reduced transcription. NLRP3 inhibition primarily addresses inflammasome activation and cytokine maturation; priming and transcription should be measured separately.
• An in vitro concentration is not an in vivo dose. The 10 μM HUVEC condition came from one cell-injury model and should not be transferred directly to animal studies or other cell types.
• Preclinical efficacy is not clinical efficacy. LPS-challenge and experimental autoimmune encephalomyelitis findings support disease-model research, but they do not establish human safety, pharmacokinetics, or therapeutic benefit.

Why this cross-domain matters, maturity, and limitations

Macrophage and endothelial systems answer related but different questions. Macrophage assays establish cytokine and inflammasome pharmacology. HUVEC assays examine whether oxidative endothelial injury includes an NLRP3-linked pyroptotic component. The cross-domain bridge is supported by the cited HUVEC study, but its maturity is preclinical and mechanistic. Cell-line behavior, hydrogen peroxide injury, and pharmacological corroboration cannot substitute for primary vascular tissue, genetic validation, or clinical evidence.

The internal article MCC950 Sodium: Advancing Precision in NLRP3 Inflammasome Research emphasizes macrophage-mediated inflammation, pyroptosis, and autoimmune models. This article extends that overview by attaching the product specifications to stable primary and peer-reviewed evidence links.

The related article Curcumin Inhibits Endothelial Pyroptosis via NLRP3 Suppression focuses on curcumin-mediated protection in HUVECs. This article clarifies the role of MCC950 as a pathway-specific pharmacological comparator rather than as the study's main therapeutic intervention.

Workflow Integration & Parameters

Use MCC950 sodium as one component of a controlled inflammasome workflow. Include untreated, stimulus-only, inhibitor-plus-stimulus, and inhibitor-only groups. Measure viability because a nonspecific cytotoxic effect can mimic reduced cytokine release. Preserve the same solvent concentration across matched groups.

Protocol Parameters

• Macrophage potency benchmark: Use the reported 7.5 nM BMDM IC50 as a literature-oriented starting benchmark, not as a guaranteed effective concentration for every donor, species, stimulus, or differentiation protocol. Product information
• HUVEC injury model: The cited study exposed HUVECs to 800 μM hydrogen peroxide for 3 hours. Treat this as a model-specific injury condition. Yuan et al., 2022
• MCC950 comparator condition: The cited HUVEC study used 10 μM MCC950 for 2 hours before or during its pharmacological experiment, as defined by the study design. Yuan et al., 2022
• Solvent preparation: The product page reports solubility of at least 124 mg/mL in water, at least 21.45 mg/mL in DMSO, and at least 43 mg/mL in ethanol under unspecified test conditions. Confirm clarity and precipitation in the actual assay medium. Product information
• Storage: Store the solid at -20°C and avoid long-term storage of solutions, following the product recommendation. Prepare fresh working solutions when stability is uncertain. Product information
• Readout pairing: Pair IL-1β with TNF-α, viability, or caspase-1 measurements to distinguish NLRP3 pathway inhibition from general secretion failure. This is a workflow recommendation rather than a numeric literature benchmark.

For mouse studies, report strain, sex, age, stimulus, administration route, treatment timing, dose, sample collection time, and cytokine assay method. The published LPS and experimental autoimmune encephalomyelitis findings demonstrate disease-model utility, but the product dossier and cited summaries do not provide enough protocol detail here to prescribe a universal animal regimen.

Conclusion & Outlook

MCC950 sodium and CRID3 sodium salt provide a focused pharmacological tool for studying NLRP3-associated inflammation. The most reproducible interpretation comes from combining selective IL-1β suppression with preserved TNF-α secretion, viability measurements, and pathway controls. The compound links macrophage inflammasome biology with selected endothelial pyroptosis experiments, while the evidence remains preclinical and model-dependent.

The cited disease-model findings support continued investigation of NLRP3 inhibition in inflammatory and autoimmune disease models. The cited HUVEC findings support use of MCC950 in mechanistic studies of oxidative endothelial injury. Future work should therefore refine model-specific exposure conditions, confirm pathway dependence with orthogonal controls, and report complete dosing and sampling parameters rather than extrapolating across systems.